Researchers found through an analysis of pooled data from various midstage and late-stage trials that an abbreviated, eight-week treatment duration of glecaprevir/pibrentasvir to treat noncirrhotic hepatitis C virus patients with genotype 3 was effective. The findings were reported online in the Journal of Viral Hepatitis.
HCV combo's shorter treatment duration effective in genotype 3
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.